Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Central Nervous System Neoplasms 3Brain Neoplasms 3Glioma 2Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1Skin Neoplasms 1Sarcoma 1Pinealoma 1Neuroma, Acoustic 1Neoplasms, Germ Cell and Embryonal 1Mouth Neoplasms 1Meningioma 1Melanoma 1Medulloblastoma 1Glioblastoma 1Ependymoma 1Craniopharyngioma 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Breast Neoplasms 1Astrocytoma 1

Interventions

Cisplatin 30Magnetic Resonance Spectroscopy 21Radiotherapy 20pembrolizumab 18Specimen Handling 17Cetuximab 16Biopsy 13Radiotherapy, Intensity-Modulated 12Radiation 11Paclitaxel 11Carboplatin 11Surveys and Questionnaires 10Fluorouracil 10Drug Therapy 101,2-diaminocyclohexaneplatinum II citrate 10Platinum 9Surgical Procedures, Operative 8X-Rays 7Taxes 7Celecoxib 7Standard of Care 6Sentinel Lymph Node Biopsy 6Observation 5Nivolumab 5cemiplimab 4Metformin 4Interviews as Topic 4Immunohistochemistry 4Fluorodeoxyglucose F18 4Docetaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mouth Neoplasms × tozuleristide × Clear all
NCT05316688 2026-02-25

A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

University of Washington

Phase 1/2 Terminated
8 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡